NTT: World’s First Successful 1.4-Tbit/s Wireless Transmission in the Sub-THz Band
17.5.2023 11:09:00 EEST | Business Wire | Press release
Aiming to implement terabit-class wireless transmission to support wireless demand in the 2030s, NTT Corporation (NTT) has successfully achieved the world’s first “orbital angular momentum (OAM) multiplexing high-capacity wireless transmission—at 1.44 Tbit/s—using an ultra-wide bandwidth of 32 GHz. As an innovative wireless-communication technology that uses the sub-terahertz (sub-THz) band, this achievement will enable wireless access to vast amounts of information at data-transfer rate exceeding 1 Tbit/s. This achievement was realized using the sub-THz band within the range from 135 GHz to 170 GHz, and is an innovative wireless communication technology that enables wireless access to a huge amount of information exceeding 1 Tbit/s. As a key element of the “Innovative Optical and Wireless Network” (IOWN), which we aim to implement with our global partners, it is an extension of the high-capacity communication network and information-processing infrastructure centered on light to wireless networks including 6G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420006084/en/
Figure 1: Image of OAM-multiplexing transmission technology and trends in high-capacity wireless transmission (Graphic: Business Wire)
Aiming to support the high-capacity network and information processing infrastructure of the IOWN and 6G and prepare for the increasing future demand for wireless communications, NTT is engaged in research and development with the goal of achieving terabit-class wireless transmission. To enhance the capacity of wireless communications, NTT is increasing the spatial multiplexing order by applying on a new principle using radio waves with “orbital angular momentum” (Figure 1) to increase wireless-transmission capacity and using the sub-terahertz (sub-THz) band to increase transmission bandwidth.
The approach taken by NTT is to use an analog circuit called a “Butler matrix” to increase the spatial multiplexing order by multiplexing multiple OAM waves. This approach reduces the enormous amount of digital signal processing required to eliminate interference between multiplexed data streams in high-capacity communications exceeding one terabit.
In this research, NTT has promoted research and development of sub-THz-band waveguide technology and succeeded in developing an antenna-integrated Butler matrix that operates with a wide bandwidth and low loss. The antenna-integrated Butler matrix is designed to simultaneously generate and separate eight different OAM waves over a very wide bandwidth, i.e., 135 to 170 GHz, which can be used to multiplex and transmit eight data signals. Moreover, by performing OAM multiplexing transmission with two different polarizations, it is possible to multiplex and transmit twice as many data signals simultaneously without them interfering. We conducted transmission tests using the antenna-integrated Butler matrix, and we achieved the world’s first successful large-capacity wireless transmission totaling 1.44 Tbit/s in the sub-THz bands of 135.5 to 151.5 GHz and 152.5 to 168.5 GHz (Figure 2). This transmission capacity is equivalent to the speed of simultaneous transmission of approximately 35,000 ultra-high-definition 4K videos (at about 40 Mbit/s) that can be available on current video websites. This speed enables the simultaneous transmission of 140 or more uncompressed 4K videos (at about 10 Gbit/s) for applications that require ultra-low latency.
This technology is expected to enable (i) broadband and high-speed wireless transmission comparable to optical transmission systems and (ii) seamless connection between wireless and optical transmission systems without the need for a complex digital signal-processing system for spatial multiplexing, since the analog circuit (i.e., the Butler matrix) handles the multiplexing of OAM waves. The next step in this development is to conduct demonstrations over longer distances (exceeding 100 m) while envisioning various applications of this technology in the real world, including wireless backhaul/fronthaul between base stations and relay transmission (Figure 3). We expect the eventual development of this technology to support the creation and spread of various future services, such as VR/AR (virtual reality/augmented reality), high-definition video transmission, connected cars, and telemedicine, as innovative wireless-communication technology in the IOWN and 6G era.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420006084/en/
Contact information
[Media Contact]
NTT Corporation,
Science and Core Technology Laboratory Group,
nttrd-pr@ml.ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
